Enhancing the stability of adalimumab by engineering additional glycosylation motifs
Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein aggregation is one of the ongoing challenges, limiting the development and application of mAbs as therapeutic pro...
Saved in:
| Published in | International journal of biological macromolecules Vol. 158; pp. 189 - 196 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.09.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0141-8130 1879-0003 1879-0003 |
| DOI | 10.1016/j.ijbiomac.2020.04.147 |
Cover
| Abstract | Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein aggregation is one of the ongoing challenges, limiting the development and application of mAbs as therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. We engineered an aggregation-prone region of adalimumab, the top selling mAb product worldwide - with additional glycosylation sites to enhance its resistance to aggregation by steric hindrance as a next generation biologic. We found that the addition of N-glycans in the Fab domain significantly enhanced its conformational stability, with some variants increasing the melting temperature of the Fab domain by >6 °C. The mutations tested had minimal impact on antigen binding affinity, or affinity to Fcγ receptors responsible for effector function. Our findings highlight the significant utility of this rational engineering approach for enhancing the conformational stability of therapeutic mAbs and other next-generation antibody formats. |
|---|---|
| AbstractList | Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein aggregation is one of the ongoing challenges, limiting the development and application of mAbs as therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. We engineered an aggregation-prone region of adalimumab, the top selling mAb product worldwide - with additional glycosylation sites to enhance its resistance to aggregation by steric hindrance as a next generation biologic. We found that the addition of N-glycans in the Fab domain significantly enhanced its conformational stability, with some variants increasing the melting temperature of the Fab domain by >6 °C. The mutations tested had minimal impact on antigen binding affinity, or affinity to Fcγ receptors responsible for effector function. Our findings highlight the significant utility of this rational engineering approach for enhancing the conformational stability of therapeutic mAbs and other next-generation antibody formats. Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein aggregation is one of the ongoing challenges, limiting the development and application of mAbs as therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. We engineered an aggregation-prone region of adalimumab, the top selling mAb product worldwide - with additional glycosylation sites to enhance its resistance to aggregation by steric hindrance as a next generation biologic. We found that the addition of N-glycans in the Fab domain significantly enhanced its conformational stability, with some variants increasing the melting temperature of the Fab domain by >6 °C. The mutations tested had minimal impact on antigen binding affinity, or affinity to Fcγ receptors responsible for effector function. Our findings highlight the significant utility of this rational engineering approach for enhancing the conformational stability of therapeutic mAbs and other next-generation antibody formats. Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein aggregation is one of the ongoing challenges, limiting the development and application of mAbs as therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. We engineered an aggregation-prone region of adalimumab, the top selling mAb product worldwide - with additional glycosylation sites to enhance its resistance to aggregation by steric hindrance as a next generation biologic. We found that the addition of N-glycans in the Fab domain significantly enhanced its conformational stability, with some variants increasing the melting temperature of the Fab domain by >6 °C. The mutations tested had minimal impact on antigen binding affinity, or affinity to Fcγ receptors responsible for effector function. Our findings highlight the significant utility of this rational engineering approach for enhancing the conformational stability of therapeutic mAbs and other next-generation antibody formats.Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and infections. Unfortunately, protein aggregation is one of the ongoing challenges, limiting the development and application of mAbs as therapeutic products by decreasing half-life, increasing immunogenicity and reducing activity. We engineered an aggregation-prone region of adalimumab, the top selling mAb product worldwide - with additional glycosylation sites to enhance its resistance to aggregation by steric hindrance as a next generation biologic. We found that the addition of N-glycans in the Fab domain significantly enhanced its conformational stability, with some variants increasing the melting temperature of the Fab domain by >6 °C. The mutations tested had minimal impact on antigen binding affinity, or affinity to Fcγ receptors responsible for effector function. Our findings highlight the significant utility of this rational engineering approach for enhancing the conformational stability of therapeutic mAbs and other next-generation antibody formats. |
| Author | Sumer-Bayraktar, Zeynep Kayser, Veysel Reslan, Mouhamad Cruz, Esteban Sifniotis, Vicki Cordwell, Stuart |
| Author_xml | – sequence: 1 givenname: Mouhamad surname: Reslan fullname: Reslan, Mouhamad email: mres7064@uni.sydney.edu.au organization: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia – sequence: 2 givenname: Vicki surname: Sifniotis fullname: Sifniotis, Vicki email: vsif0221@uni.sydney.edu.au organization: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia – sequence: 3 givenname: Esteban surname: Cruz fullname: Cruz, Esteban email: esteban.cruzgonzalez@sydney.edu.au organization: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia – sequence: 4 givenname: Zeynep surname: Sumer-Bayraktar fullname: Sumer-Bayraktar, Zeynep email: zeynep.sumerbayraktar@sydney.edu.au organization: School of Life and Environmental Sciences, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia – sequence: 5 givenname: Stuart surname: Cordwell fullname: Cordwell, Stuart email: stuart.cordwell@sydney.edu.au organization: School of Life and Environmental Sciences, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia – sequence: 6 givenname: Veysel surname: Kayser fullname: Kayser, Veysel email: veysel.kayser@sydney.edu.au organization: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32360204$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcFq3DAQhkVJaTZpXyH42IudkaWVbeihJaRNIdBLehZjabzRIkuppS347WN3s5de9iRGfN8MM_8VuwgxEGM3HCoOXN3uK7fvXRzRVDXUUIGsuGzesQ1vm64EAHHBNsAlL1su4JJdpbRfftWWtx_YpaiFWiy5YU_34RmDcWFX5GcqUsbeeZfnIg4FWvRuPIzYF_1cUNi5QDStKFrrsosBfbHzs4lp9rjWxRizG9JH9n5An-jT23vNfn-_f7p7KB9__fh59-2xNFI1ucQt2IE3VvVDB7WsBxCmMSSVNbYhK6CuCYYWh4bqtgWDhNBjJw2qHpREcc0-H_u-TPHPgVLWo0uGvMdA8ZB0LUUnWqU6cR4VXcu3Qm5X9OYNPfQjWf0yuRGnWZ-OtgBfjoCZYkoTDdq4_G__PKHzmoNeM9J7fcpIrxlpkHrJaNHVf_ppwlnx61Gk5aZ_HU06GUfBkHUTmaxtdOdavAKEdrCn |
| CitedBy_id | crossref_primary_10_1038_s41598_024_64938_0 crossref_primary_10_1002_prot_26603 crossref_primary_10_1093_jb_mvaa116 crossref_primary_10_1039_D1CB00067E crossref_primary_10_1016_j_autrev_2021_102849 crossref_primary_10_2139_ssrn_3954862 crossref_primary_10_1016_j_autrev_2021_102804 crossref_primary_10_1007_s12257_023_0078_4 crossref_primary_10_1016_j_xphs_2025_103771 crossref_primary_10_1016_j_enzmictec_2022_110072 crossref_primary_10_2174_138920102311220624142738 crossref_primary_10_3390_molecules27248859 crossref_primary_10_3390_pharmaceutics13111747 |
| Cites_doi | 10.1016/j.addr.2016.11.004 10.1002/pro.372 10.1007/s12551-018-0407-6 10.1002/jps.21104 10.3390/antib7020017 10.1016/j.bbrc.2018.06.071 10.4161/mabs.29680 10.1016/j.ab.2016.03.007 10.1080/19420862.2016.1259046 10.1007/s11095-014-1541-x 10.1021/acs.molpharmaceut.6b00255 10.4161/mabs.29938 10.1021/acs.biomac.7b01507 10.1074/mcp.M117.066944 10.1080/19420862.2017.1320463 10.1007/s11095-015-1627-0 10.1016/j.xphs.2016.11.021 10.1016/j.csbj.2017.01.003 10.1093/nar/gkv359 10.1073/pnas.0904191106 10.1007/s10822-016-9914-3 10.4161/19420862.2015.989042 10.1038/nrd.2016.268 10.1002/jps.24520 10.1021/acs.bioconjchem.7b00389 10.1038/nrd.2018.42 10.1002/jps.22493 10.1002/mabi.201700372 10.1080/19420862.2015.1112477 10.1016/j.clim.2009.01.002 |
| ContentType | Journal Article |
| Copyright | 2020 Copyright © 2020. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2020 – notice: Copyright © 2020. Published by Elsevier B.V. |
| DBID | AAYXX CITATION NPM 7X8 7S9 L.6 |
| DOI | 10.1016/j.ijbiomac.2020.04.147 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Engineering |
| EISSN | 1879-0003 |
| EndPage | 196 |
| ExternalDocumentID | 32360204 10_1016_j_ijbiomac_2020_04_147 S0141813020330087 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABFRF ABGSF ABJNI ABMAC ABUDA ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC CS3 DOVZS DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SPCBC SSU SSZ T5K UNMZH ~02 ~G- 29J AAHBH AAQXK AATTM AAXKI AAYWO AAYXX ABFNM ABWVN ABXDB ACRPL ACVFH ADCNI ADMUD ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRDE AGRNS AHHHB AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CITATION EJD FEDTE FGOYB G-2 HLW HVGLF HZ~ R2- RIG SBG SEW SSH UHS WUQ NPM 7X8 ACLOT EFKBS ~HD 7S9 L.6 |
| ID | FETCH-LOGICAL-c467t-a50df17d6bf90242f03c7ce46dcd7ed3022e0f8af7e2880caea0ba94ca6b064a3 |
| IEDL.DBID | AIKHN |
| ISSN | 0141-8130 1879-0003 |
| IngestDate | Sat Sep 27 22:58:17 EDT 2025 Sun Sep 28 07:21:06 EDT 2025 Wed Feb 19 02:09:39 EST 2025 Thu Apr 24 23:04:52 EDT 2025 Tue Jul 01 01:03:54 EDT 2025 Fri Feb 23 02:47:09 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Biobetters SAP APR SE-HPLC AdmAb Tagg BCM mAb Aggregation Monoclonal antibodies Tm KD SLS WT |
| Language | English |
| License | Copyright © 2020. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c467t-a50df17d6bf90242f03c7ce46dcd7ed3022e0f8af7e2880caea0ba94ca6b064a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 32360204 |
| PQID | 2398153453 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2439386693 proquest_miscellaneous_2398153453 pubmed_primary_32360204 crossref_citationtrail_10_1016_j_ijbiomac_2020_04_147 crossref_primary_10_1016_j_ijbiomac_2020_04_147 elsevier_sciencedirect_doi_10_1016_j_ijbiomac_2020_04_147 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-09-01 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | International journal of biological macromolecules |
| PublicationTitleAlternate | Int J Biol Macromol |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Fleischman, Chung, Paul, Lewus (bb0025) 2017; 106 Reslan, Demir, Trout, Chan, Kayser (bb0050) 2016 Zambrano, Jamroz, Szczasiuk, Pujols, Kmiecik, Ventura (bb0100) 2015; 43 Lerch, Sharpe, Mayclin (bb0135) 2017; 9 Kayser, Chennamsetty, Voynov, Helk, Forrer, Trout (bb0035) 2011; 100 Nakamura, Oda-Ueda, Ueda, Ohkuri (bb0125) 2018; 503 Klein (bb0015) 2018; 7 Reslan, Kayser (bb0065) 2016 Bessa, Boeckle, Beck (bb0040) 2015; 32 Kuyucak, Kayser (bb0105) 2017; 15 Elgundi, Reslan, Cruz, Sifniotis, Kayser (bb0020) 2017; 122 Urquhart (bb0005) 2018; 17 van de Bovenkamp, Derksen, van Breemen (bb0160) 2018; 9 Beck, Goetsch, Dumontet, Corvaïa (bb0030) 2017; 16 Sridhar, Janczy, Hatlevik, Wolfson, Anseth, Tibbitt (bb0070) 2018; 19 Ahmadi, Bryson, Cloake (bb0045) 2015; 32 Zhang, Frey, Corcoran, Zhang-van Enk, Subramony (bb0055) 2016; 13 Ionescu, Vlasak, Price, Kirchmeier (bb0165) 2008; 97 Pepinsky, Laura, BS (bb0130) 2010; 19 Hayes, Frostell, Karlsson (bb0145) 2017; 16 Lee, Ko, Mansfield, Nauka, Bat, Maynard (bb0075) 2018; 18 McConnell, Zhang, Macomber (bb0115) 2014; 6 Reslan, Kayser (bb0085) 2018; 10 Ecker, Jones, Levine (bb0010) 2015; 7 Courtois, Schneider, Agrawal, Trout (bb0110) 2015; 104 Bansal, Dhawan, Chattopadhyay, Maurya, Haridas, Rathore (bb0080) 2017; 28 Chennamsetty, Voynov, Kayser, Helk, Trout (bb0090) 2009; 106 Kulshreshtha, Chaudhary, Goswami, Mathur (bb0095) 2016; 30 Respaud, Marchand, Parent (bb0060) 2014; 6 Courtois, Agrawal, Lauer, Trout (bb0120) 2016; 8 Karlsson, Pol, Frostell (bb0140) 2016; 502 Kaymakcalan, Sakorafas, Bose (bb0150) 2009; 131 Magnenat, Palmese, Fremaux (bb0155) 2017; 9 Kuyucak (10.1016/j.ijbiomac.2020.04.147_bb0105) 2017; 15 Nakamura (10.1016/j.ijbiomac.2020.04.147_bb0125) 2018; 503 Courtois (10.1016/j.ijbiomac.2020.04.147_bb0110) 2015; 104 Ahmadi (10.1016/j.ijbiomac.2020.04.147_bb0045) 2015; 32 Klein (10.1016/j.ijbiomac.2020.04.147_bb0015) 2018; 7 Fleischman (10.1016/j.ijbiomac.2020.04.147_bb0025) 2017; 106 Hayes (10.1016/j.ijbiomac.2020.04.147_bb0145) 2017; 16 Kaymakcalan (10.1016/j.ijbiomac.2020.04.147_bb0150) 2009; 131 Ionescu (10.1016/j.ijbiomac.2020.04.147_bb0165) 2008; 97 Bansal (10.1016/j.ijbiomac.2020.04.147_bb0080) 2017; 28 Reslan (10.1016/j.ijbiomac.2020.04.147_bb0050) 2016 Lee (10.1016/j.ijbiomac.2020.04.147_bb0075) 2018; 18 Elgundi (10.1016/j.ijbiomac.2020.04.147_bb0020) 2017; 122 McConnell (10.1016/j.ijbiomac.2020.04.147_bb0115) 2014; 6 Bessa (10.1016/j.ijbiomac.2020.04.147_bb0040) 2015; 32 Courtois (10.1016/j.ijbiomac.2020.04.147_bb0120) 2016; 8 Lerch (10.1016/j.ijbiomac.2020.04.147_bb0135) 2017; 9 Reslan (10.1016/j.ijbiomac.2020.04.147_bb0065) 2016 Kulshreshtha (10.1016/j.ijbiomac.2020.04.147_bb0095) 2016; 30 Kayser (10.1016/j.ijbiomac.2020.04.147_bb0035) 2011; 100 van de Bovenkamp (10.1016/j.ijbiomac.2020.04.147_bb0160) 2018; 9 Karlsson (10.1016/j.ijbiomac.2020.04.147_bb0140) 2016; 502 Reslan (10.1016/j.ijbiomac.2020.04.147_bb0085) 2018; 10 Sridhar (10.1016/j.ijbiomac.2020.04.147_bb0070) 2018; 19 Zambrano (10.1016/j.ijbiomac.2020.04.147_bb0100) 2015; 43 Pepinsky (10.1016/j.ijbiomac.2020.04.147_bb0130) 2010; 19 Magnenat (10.1016/j.ijbiomac.2020.04.147_bb0155) 2017; 9 Chennamsetty (10.1016/j.ijbiomac.2020.04.147_bb0090) 2009; 106 Ecker (10.1016/j.ijbiomac.2020.04.147_bb0010) 2015; 7 Zhang (10.1016/j.ijbiomac.2020.04.147_bb0055) 2016; 13 Urquhart (10.1016/j.ijbiomac.2020.04.147_bb0005) 2018; 17 Respaud (10.1016/j.ijbiomac.2020.04.147_bb0060) 2014; 6 Beck (10.1016/j.ijbiomac.2020.04.147_bb0030) 2017; 16 |
| References_xml | – volume: 6 start-page: 1347 year: 2014 end-page: 1355 ident: bb0060 article-title: Effect of formulation on the stability and aerosol performance of a nebulized antibody publication-title: mAbs – volume: 8 start-page: 99 year: 2016 end-page: 112 ident: bb0120 article-title: Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab publication-title: mAbs – volume: 32 start-page: 1383 year: 2015 end-page: 1394 ident: bb0045 article-title: Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics publication-title: Pharm. Res. – start-page: 1 year: 2016 end-page: 7 ident: bb0065 article-title: The effect of deuterium oxide on the conformational stability and aggregation of bovine serum albumin publication-title: Pharm. Dev. Technol. – volume: 106 start-page: 994 year: 2017 end-page: 1000 ident: bb0025 article-title: Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies publication-title: J. Pharm. Sci. – volume: 28 start-page: 2549 year: 2017 end-page: 2559 ident: bb0080 article-title: Peptide dendrons as thermal-stability amplifiers for immunoglobulin G1 monoclonal antibody biotherapeutics publication-title: Bioconjug. Chem. – volume: 106 start-page: 11937 year: 2009 end-page: 11942 ident: bb0090 article-title: Design of therapeutic proteins with enhanced stability publication-title: Proc. Natl. Acad. Sci. – volume: 16 start-page: 1770 year: 2017 end-page: 1788 ident: bb0145 article-title: Identification of Fc Gamma receptor glycoforms that produce differential binding kinetics for rituximab publication-title: Mol. Cell. Proteomics – volume: 19 start-page: 740 year: 2018 end-page: 747 ident: bb0070 article-title: Thermal stabilization of biologics with photoresponsive hydrogels publication-title: Biomacromolecules – volume: 43 start-page: W306 year: 2015 end-page: W313 ident: bb0100 article-title: AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures publication-title: Nucleic Acids Res. – volume: 19 start-page: 954 year: 2010 end-page: 966 ident: bb0130 article-title: Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis publication-title: Protein Sci. – volume: 503 start-page: 752 year: 2018 end-page: 756 ident: bb0125 article-title: Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab publication-title: Biochem. Biophys. Res. Commun. – volume: 13 start-page: 3362 year: 2016 end-page: 3369 ident: bb0055 article-title: Influence of arginine salts on the thermal stability and aggregation kinetics of monoclonal antibody: dominant role of anions publication-title: Mol. Pharm. – start-page: 1 year: 2016 end-page: 7 ident: bb0050 article-title: Lack of a synergistic effect of arginine–glutamic acid on the physical stability of spray-dried bovine serum albumin publication-title: Pharm. Dev. Technol. – volume: 131 start-page: 308 year: 2009 end-page: 316 ident: bb0150 article-title: Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor publication-title: Clin. Immunol. – volume: 100 start-page: 2526 year: 2011 end-page: 2542 ident: bb0035 article-title: Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation publication-title: J. Pharm. Sci. – volume: 30 start-page: 401 year: 2016 end-page: 412 ident: bb0095 article-title: Computational approaches for predicting mutant protein stability publication-title: J. Comput. Aided Mol. Des. – volume: 6 start-page: 1274 year: 2014 end-page: 1282 ident: bb0115 article-title: A general approach to antibody thermostabilization publication-title: MAbs – volume: 502 start-page: 53 year: 2016 end-page: 63 ident: bb0140 article-title: Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data publication-title: Anal. Biochem. – volume: 7 start-page: 17 year: 2018 ident: bb0015 article-title: Special issue: monoclonal antibodies publication-title: Antibodies – volume: 16 start-page: 315 year: 2017 ident: bb0030 article-title: Strategies and challenges for the next generation of antibody–drug conjugates publication-title: Nat. Rev. Drug Discov. – volume: 7 start-page: 9 year: 2015 end-page: 14 ident: bb0010 article-title: The therapeutic monoclonal antibody market publication-title: mAbs – volume: 9 start-page: 127 year: 2017 end-page: 139 ident: bb0155 article-title: Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira® publication-title: mAbs – volume: 17 start-page: 232 year: 2018 ident: bb0005 article-title: Top drugs and companies by sales in 2017 publication-title: Nat. Rev. Drug Discov. – volume: 104 start-page: 2433 year: 2015 end-page: 2440 ident: bb0110 article-title: Rational design of biobetters with enhanced stability publication-title: J. Pharm. Sci. – volume: 18 year: 2018 ident: bb0075 article-title: Glucose-responsive trehalose hydrogel for insulin stabilization and delivery publication-title: Macromol. Biosci. – volume: 122 start-page: 2 year: 2017 end-page: 19 ident: bb0020 article-title: The state-of-play and future of antibody therapeutics publication-title: Adv. Drug Deliv. Rev. – volume: 9 start-page: 874 year: 2017 end-page: 883 ident: bb0135 article-title: Infliximab crystal structures reveal insights into self-association publication-title: mAbs – volume: 15 start-page: 138 year: 2017 end-page: 145 ident: bb0105 article-title: Biobetters from an integrated computational/experimental approach publication-title: Comput Struct Biotechnol J – volume: 9 start-page: 740 year: 2018 ident: bb0160 article-title: Variable Domain N-linked Glycans Acquired During Antigen-specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability – volume: 97 start-page: 1414 year: 2008 end-page: 1426 ident: bb0165 article-title: Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies publication-title: J. Pharm. Sci. – volume: 32 start-page: 2344 year: 2015 end-page: 2359 ident: bb0040 article-title: The immunogenicity of antibody aggregates in a novel transgenic mouse model publication-title: Pharm. Res. – volume: 10 start-page: 781 year: 2018 end-page: 793 ident: bb0085 article-title: Ionic liquids as biocompatible stabilizers of proteins publication-title: Biophys. Rev. – volume: 122 start-page: 2 issue: Supplement C year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0020 article-title: The state-of-play and future of antibody therapeutics publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2016.11.004 – volume: 19 start-page: 954 issue: 5 year: 2010 ident: 10.1016/j.ijbiomac.2020.04.147_bb0130 article-title: Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis publication-title: Protein Sci. doi: 10.1002/pro.372 – volume: 10 start-page: 781 issue: 3 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0085 article-title: Ionic liquids as biocompatible stabilizers of proteins publication-title: Biophys. Rev. doi: 10.1007/s12551-018-0407-6 – volume: 97 start-page: 1414 issue: 4 year: 2008 ident: 10.1016/j.ijbiomac.2020.04.147_bb0165 article-title: Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies publication-title: J. Pharm. Sci. doi: 10.1002/jps.21104 – volume: 7 start-page: 17 issue: 2 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0015 article-title: Special issue: monoclonal antibodies publication-title: Antibodies doi: 10.3390/antib7020017 – volume: 9 start-page: 740 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0160 – volume: 503 start-page: 752 issue: 2 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0125 article-title: Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2018.06.071 – volume: 6 start-page: 1274 issue: 5 year: 2014 ident: 10.1016/j.ijbiomac.2020.04.147_bb0115 article-title: A general approach to antibody thermostabilization publication-title: MAbs doi: 10.4161/mabs.29680 – volume: 502 start-page: 53 year: 2016 ident: 10.1016/j.ijbiomac.2020.04.147_bb0140 article-title: Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data publication-title: Anal. Biochem. doi: 10.1016/j.ab.2016.03.007 – volume: 9 start-page: 127 issue: 1 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0155 article-title: Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira® publication-title: mAbs doi: 10.1080/19420862.2016.1259046 – volume: 32 start-page: 1383 issue: 4 year: 2015 ident: 10.1016/j.ijbiomac.2020.04.147_bb0045 article-title: Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics publication-title: Pharm. Res. doi: 10.1007/s11095-014-1541-x – volume: 13 start-page: 3362 issue: 10 year: 2016 ident: 10.1016/j.ijbiomac.2020.04.147_bb0055 article-title: Influence of arginine salts on the thermal stability and aggregation kinetics of monoclonal antibody: dominant role of anions publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.6b00255 – volume: 6 start-page: 1347 issue: 5 year: 2014 ident: 10.1016/j.ijbiomac.2020.04.147_bb0060 article-title: Effect of formulation on the stability and aerosol performance of a nebulized antibody publication-title: mAbs doi: 10.4161/mabs.29938 – volume: 19 start-page: 740 issue: 3 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0070 article-title: Thermal stabilization of biologics with photoresponsive hydrogels publication-title: Biomacromolecules doi: 10.1021/acs.biomac.7b01507 – volume: 16 start-page: 1770 issue: 10 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0145 article-title: Identification of Fc Gamma receptor glycoforms that produce differential binding kinetics for rituximab publication-title: Mol. Cell. Proteomics doi: 10.1074/mcp.M117.066944 – volume: 9 start-page: 874 issue: 5 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0135 article-title: Infliximab crystal structures reveal insights into self-association publication-title: mAbs doi: 10.1080/19420862.2017.1320463 – volume: 32 start-page: 2344 issue: 7 year: 2015 ident: 10.1016/j.ijbiomac.2020.04.147_bb0040 article-title: The immunogenicity of antibody aggregates in a novel transgenic mouse model publication-title: Pharm. Res. doi: 10.1007/s11095-015-1627-0 – volume: 106 start-page: 994 issue: 4 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0025 article-title: Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies publication-title: J. Pharm. Sci. doi: 10.1016/j.xphs.2016.11.021 – volume: 15 start-page: 138 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0105 article-title: Biobetters from an integrated computational/experimental approach publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2017.01.003 – volume: 43 start-page: W306 issue: W1 year: 2015 ident: 10.1016/j.ijbiomac.2020.04.147_bb0100 article-title: AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkv359 – volume: 106 start-page: 11937 issue: 29 year: 2009 ident: 10.1016/j.ijbiomac.2020.04.147_bb0090 article-title: Design of therapeutic proteins with enhanced stability publication-title: Proc. Natl. Acad. Sci. doi: 10.1073/pnas.0904191106 – volume: 30 start-page: 401 issue: 5 year: 2016 ident: 10.1016/j.ijbiomac.2020.04.147_bb0095 article-title: Computational approaches for predicting mutant protein stability publication-title: J. Comput. Aided Mol. Des. doi: 10.1007/s10822-016-9914-3 – volume: 7 start-page: 9 issue: 1 year: 2015 ident: 10.1016/j.ijbiomac.2020.04.147_bb0010 article-title: The therapeutic monoclonal antibody market publication-title: mAbs doi: 10.4161/19420862.2015.989042 – start-page: 1 year: 2016 ident: 10.1016/j.ijbiomac.2020.04.147_bb0065 article-title: The effect of deuterium oxide on the conformational stability and aggregation of bovine serum albumin publication-title: Pharm. Dev. Technol. – volume: 16 start-page: 315 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0030 article-title: Strategies and challenges for the next generation of antibody–drug conjugates publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2016.268 – volume: 104 start-page: 2433 issue: 8 year: 2015 ident: 10.1016/j.ijbiomac.2020.04.147_bb0110 article-title: Rational design of biobetters with enhanced stability publication-title: J. Pharm. Sci. doi: 10.1002/jps.24520 – volume: 28 start-page: 2549 issue: 10 year: 2017 ident: 10.1016/j.ijbiomac.2020.04.147_bb0080 article-title: Peptide dendrons as thermal-stability amplifiers for immunoglobulin G1 monoclonal antibody biotherapeutics publication-title: Bioconjug. Chem. doi: 10.1021/acs.bioconjchem.7b00389 – volume: 17 start-page: 232 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0005 article-title: Top drugs and companies by sales in 2017 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.42 – start-page: 1 year: 2016 ident: 10.1016/j.ijbiomac.2020.04.147_bb0050 article-title: Lack of a synergistic effect of arginine–glutamic acid on the physical stability of spray-dried bovine serum albumin publication-title: Pharm. Dev. Technol. – volume: 100 start-page: 2526 issue: 7 year: 2011 ident: 10.1016/j.ijbiomac.2020.04.147_bb0035 article-title: Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation publication-title: J. Pharm. Sci. doi: 10.1002/jps.22493 – volume: 18 issue: 5 year: 2018 ident: 10.1016/j.ijbiomac.2020.04.147_bb0075 article-title: Glucose-responsive trehalose hydrogel for insulin stabilization and delivery publication-title: Macromol. Biosci. doi: 10.1002/mabi.201700372 – volume: 8 start-page: 99 issue: 1 year: 2016 ident: 10.1016/j.ijbiomac.2020.04.147_bb0120 article-title: Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab publication-title: mAbs doi: 10.1080/19420862.2015.1112477 – volume: 131 start-page: 308 issue: 2 year: 2009 ident: 10.1016/j.ijbiomac.2020.04.147_bb0150 article-title: Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor publication-title: Clin. Immunol. doi: 10.1016/j.clim.2009.01.002 |
| SSID | ssj0006518 |
| Score | 2.3679833 |
| Snippet | Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of many debilitating diseases such as cancers, auto-immune disorders and... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 189 |
| SubjectTerms | Aggregation antigens binding capacity Biobetters engineering glycosylation half life immunogenicity melting point Monoclonal antibodies mutation neoplasms receptors therapeutics |
| Title | Enhancing the stability of adalimumab by engineering additional glycosylation motifs |
| URI | https://dx.doi.org/10.1016/j.ijbiomac.2020.04.147 https://www.ncbi.nlm.nih.gov/pubmed/32360204 https://www.proquest.com/docview/2398153453 https://www.proquest.com/docview/2439386693 |
| Volume | 158 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDLZgHOCCeL9RkLiWdU2btEc0gQYITiBxi5I0gU3QIbYdduG3Y_cxQOJx4NgqliIntr8k9meAY7QhH-OxIvAySQLizkGbM2hX0jhpMeDqknj--kb07uLL--R-DrpNLQylVda-v_Lppbeu_7RrbbZf-v02pSVheOL0lMaJWW0eFiKM9mkLFk4vrno3M4cskvKaj8YHJPCpUHhw0h9QnbsmNsMoJNbTDnVa-T5G_YRBy1h0vgLLNYhkp9U8V2HOFWuw2G16t63D7VnxSEQaxQNDgMcQAZY5sFM29EznCL2fJ8_aMDNl7oOPkFFuUXU1yB6epnY4mlaJcowS9vxoA-7Oz267vaDunxBYdH_jQCdh7jsyF8ZnFIp9yK20Lha5zaXLUXORC32qvXQRmrHVTodGZ7HVwiBS0XwTWsWwcNvAEGQk0iIcyUwWS25TbYV2oc28TnMv3A4kjcaUrcnFqcfFk2qyyAaq0bQiTaswxlOH3IH2TO6lotf4UyJrFkR92SgKY8CfskfNCipcEHoa0YUbTkaKWBDR98cJ_2UMYjeeCpHhmK1q-Wdz5hEXVGa8-4_Z7cESfVUJbPvQGr9O3AEinrE5hPmTt85hva_fARdNASQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDLZgHOCCeDOeQeJaVpY2WY9oAo3XTkPiFiVpApugm9h22L_H7mOAxOPAtY2lyIntL4n9GeAUbchHeKwIvIzjgLhz0OYM2pU0TloMuDonnr_vis5DdPMYPy5Au6qFobTK0vcXPj331uWXRqnNxqjfb1BaEoYnTk9pnJjVFmEpoqbWNVi6uL7tdOcOWcT5NR-ND0jgU6Hw4Kw_oDp3TWyGzZBYT8-p08r3MeonDJrHoqs1WC1BJLso5rkOCy7bgOV21bttE3qX2TMRaWRPDAEeQwSY58DO2NAznSL0fp2-asPMjLkPPkJGuUXF1SB7epnZ4XhWJMoxStjz4y14uLrstTtB2T8hsOj-JoGOw9Sfy1QYn1Ao9iG30rpIpDaVLkXNNV3oW9pL10Qzttrp0OgksloYRCqab0MtG2ZuFxiCjFhahCOJSSLJbUtboV1oE69bqReuDnGlMWVLcnHqcfGiqiyygao0rUjTKozw1CHr0JjLjQp6jT8lkmpB1JeNojAG_Cl7Uq2gwgWhpxGdueF0rIgFEX1_FPNfxiB24y0hEhyzUyz_fM68yQWVGe_9Y3bHsNzp3d-pu-vu7T6s0J8ime0AapO3qTtE9DMxR-XufgclqQMK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhancing+the+stability+of+adalimumab+by+engineering+additional+glycosylation+motifs&rft.jtitle=International+journal+of+biological+macromolecules&rft.au=Reslan%2C+Mouhamad&rft.au=Sifniotis%2C+Vicki&rft.au=Cruz%2C+Esteban&rft.au=Sumer-Bayraktar%2C+Zeynep&rft.date=2020-09-01&rft.issn=0141-8130&rft.volume=158+p.189-196&rft.spage=189&rft.epage=196&rft_id=info:doi/10.1016%2Fj.ijbiomac.2020.04.147&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0141-8130&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0141-8130&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0141-8130&client=summon |